RecruitingPhase 1NCT06239467
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Studying Rare malignant breast tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- OnKure, Inc.
- Principal Investigator
- OnKure, Inc.
- Intervention
- OKI-219(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (20)
- California Cancer Associates for Research and Excellence, Encinitas, California, United States
- University of California San Diego UCSD, La Jolla, California, United States
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
- Hoag - Huntington Beach, Newport Beach, California, United States
- Regents of the University of Colorado, Aurora, Colorado, United States
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Karmanos Cancer Insitute, Detroit, Michigan, United States
- Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
- Stony Brook University, Stony Brook, New York, United States
- SCRI Oncology Partners - Nashville, Nashville, Tennessee, United States
- NEXT Oncology Virginia, Fairfax, Virginia, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- Institut Jules Bordet, Anderlecht, Belgium
- UZ Leuven - Campus Gasthuisberg, Leuven, Belgium
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06239467 on ClinicalTrials.govOther trials for Rare malignant breast tumor
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT06255808Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic SensorSeoul National University Hospital
- RECRUITINGNANCT06523452Laser Speckle Imaging During Breast ReconstructionRoyal Devon and Exeter NHS Foundation Trust
- ACTIVE NOT RECRUITINGPHASE1NCT06206837A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.Pfizer
- ACTIVE NOT RECRUITINGNANCT06234488Multi-Institutional Transgender & Gender-Diverse Breast Cancer StudyMedical College of Wisconsin
- RECRUITINGPHASE2NCT05601440Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerCanadian Cancer Trials Group
- ENROLLING BY INVITATIONNANCT07206888Advanced Ultrasound Signal Processing of Suspicious Breast ImagesJohns Hopkins University
- ACTIVE NOT RECRUITINGPHASE3NCT01674140S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerSWOG Cancer Research Network
- ACTIVE NOT RECRUITINGPHASE3NCT01349322Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by SurgeryRadiation Therapy Oncology Group